Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report
ConclusionThe final model explained the most variance in psychological (68%) and physical (67%) QoL. Less variance was explained for environmental (43%) and social QoL (33%), highlighting a need for further exploration of predictors in these domains. Strategies such as functional remediation may have potential to support QoL for individuals with persistent depressive symptoms.Clinical Trials RegistryClinicalTrials.gov identifier: NCT016557.
Source: CNS Drugs - Category: Neurology Source Type: research
More News: Abilify | Canada Health | Clinical Trials | Depression | Disability | Environmental Health | International Medicine & Public Health | Lexapro | Neurology | Psychology | Study | WHO